Combating antibiotic resistance using guidelines and enhanced stewardship in Kenya: a protocol for an implementation science approach

Jesse Gitaka,1 Moses Kamita,1 Dominic Mureithi,2 Davies Ndegwa,3 Moses Masika,4 Geoffrey Omuse,5 Moses Ngari,6 Francis Makokha,1 Peter Mwaura,1 Ronald Mathai,1 Francis Muregi,1 Matilu Mwau7


ABSTRACT
Introduction Antimicrobial resistance (AMR) is a growing problem globally especially in Sub-Saharan Africa including Kenya. Without any intervention, lower/middle-income countries (LMICs) will be most affected due to already higher AMR levels compared with higher income countries and due to the far higher burden of diseases in the LMICs. Studies have consistently shown that inappropriate use of antimicrobials is the major driver of AMR. To address this challenge, hospitals are now implementing antibiotic stewardship programmes (ASPs), which have been shown to achieve reduced antibiotic usage, to decrease the prevalence of resistance and lead to significant economic benefits. However, the implementation of the guideline is highly dependent on the settings in which they are rolled out. This study, employing an implementation science approach, aims to address the knowledge gap in this area and provide critical data as well as practical experiences when using antibiotic guidelines and stewardship programmes in the public health sector. This will provide evidence of ASP performance and potentially contribute to the county, national and regional policies on antibiotics use.

Methods and analysis The study will be conducted in three geographically diverse regions, each represented by two hospitals. A baseline study on antibiotic usage, resistance and de-escalation, duration of hospital stay, rates of readmission and costs will be carried out in the preimplementation phase. The intervention, that is, the use of antibiotic guidelines and ASPs will be instituted for 18 months using a stepwise implementation strategy that will facilitate learning and continuous improvement of stewardship activities and updating of guidelines to reflect the evolving antibiotic needs.

Ethics and dissemination Approvals to carry out the study have been obtained from the National Commission for Science, Technology and Innovation and the Mount Kenya University Ethics Review Committee. The approvals from the two institutions were used to obtain permission to conduct the study at each of the participating hospitals. Study findings will be presented to policy stakeholders and published in peer-reviewed scientific journals. It is anticipated that the findings will inform the appropriate antibiotic use guidelines within our local context.

Strengths and limitations of this study
► First study aimed at concurrently rolling out antimicrobial stewardship committees in multiple hospitals in Kenya.
► Use of implementation approach to support implementation of suggested guidelines for antimicrobial resistance surveillance.
► First-hand evidence on the antimicrobial resistance in three diverse counties in Kenya.
► The study is limited to only 3 of the 47 counties in Kenya.

INTRODUCTION
Antibiotic resistance is a serious public health concern globally1 2 and locally,3 4 and fears of running out of antibiotic options in the near future have been expressed. In 2016, WHO called for immediate and concerted efforts to mitigate this threat to global health, which was estimated to contribute to 700 000 deaths in 2014 and projected to cause 10 million deaths in 2050, if inadequately mitigated.5 The driving force escalating rates of resistance is the injudicious use of antibiotics in patients, in livestock and in agriculture, and its unchecked release into the environment.6 These forces raise and increase the spread of resistant pathogens that may emerge by mutations or acquisition of plasmids carrying resistance genes.7 In one study, prior antibiotic exposure was the key independent risk factor for the acquisition of antibiotic multidrug resistance.8 Broad-spectrum antibiotics have the unintended consequence of selecting multidrug-resistant pathogens and increasing the likelihood of infection with fungi and Clostridium difficile.9

The injudicious use of antibiotics is widespread. In Africa, many patients do not receive treatment from the conventional healthcare
Antibiotic resistance is a major health challenge globally. Studies in Kenya have shown rising antibiotic resistance over the last three decades. While antibiotic guidelines and ASPs have been observed to lead to significant economic benefits, reduce antibiotic usage and lower the prevalence of resistance especially in Europe, North America, Japan and South Africa, they have not been employed to tackle the challenge in the public health sector in Kenya. The GARP report of 2011 recognised the use of guidelines and stewardship programmes as a potential strategy in ‘saving antibiotics’ but noted the need for local studies to understand implementation challenges, derive lessons and embed the strategy within the Kenyan healthcare system. The here proposed study, employing an implementation science approach, aims to address the knowledge and research gap in this area and provide critical data and experiences in using antibiotic guidelines and stewardship programmes in the public health sector.

**JUSTIFICATION**

Antibiotic resistance is a major health challenge globally. Studies in Kenya have shown rising antibiotic resistance over the last three decades. While antibiotic guidelines and ASPs have been observed to lead to significant economic benefits, reduce antibiotic usage and lower the prevalence of resistance especially in Europe, North America, Japan and South Africa, they have not been employed to tackle the challenge in the public health sector in Kenya. The GARP report of 2011 recognised the use of guidelines and stewardship programmes as a potential strategy in ‘saving antibiotics’ but noted the need for local studies to understand implementation challenges, derive lessons and embed the strategy within the Kenyan healthcare system. The here proposed study, employing an implementation science approach, aims to address the knowledge and research gap in this area and provide critical data and experiences in using antibiotic guidelines and stewardship programmes in the public health sector.

**OBJECTIVES OF THE STUDY**

**General objectives**

The overall aim is to evaluate the impact of antibiotic guidelines for empirical treatment of (1) urinary tract infections, (2) community-acquired pneumonia, (3) bacteraemia and (4) meningitis in terms of reducing usage of broad-spectrum antibiotics, antibiotic de-escalation, duration of hospital stays, rates of readmission and prevalence of antibiotic resistance in six county hospitals in Kenya.

**Specific objectives**

1. To develop guidelines for antibiotic use for common infections.
2. To set up antibiotic steward committees (ASCs) in six county hospitals.
3. To train the ASC members such that they can fully perform their mandate.
4. To measure the usage of broad-spectrum antibiotics, antibiotic de-escalation, duration of hospital stays and rates of readmission in hospitals using the antibiotic stewardship strategy.
5. To ascertain antibiotic resistance patterns using culture, sensitivity and genetic markers.
6. To establish the knowledge of healthcare workers, their attitudes and prescription practices regarding antibiotics resistance, use of guidelines and ASPs.
7. To evaluate the economic benefits of using guidelines for antibiotics use and ASPs.

**Expected outputs of the research**

1. Antibiotic guidelines informed by local bacteria susceptibility patterns.
2. ASCs in six county hospitals in Kenya.
3. Trained ASC members.
4. Data on antibiotics usage, antibiotic de-escalation, duration of hospital stay and rates of readmission in hospitals using the antibiotic stewardship strategy.
5. Map and data of antibiotic resistance patterns before and after implementation of the strategy.
6. Qualitative data on the knowledge of healthcare workers, their attitudes and practices regarding antibiotic usage and stewardship programmes.
7. Publication on cost–benefit analysis (CBA) for using antibiotic guidelines and ASPs.

**METHODS AND ANALYSIS**

**Setting**

To be able to evaluate the antibiotic stewardship strategy across Kenya using an implementation science approach, the study will be conducted in six county hospitals, namely (1) Kiambu County Referral Hospital, (2) Bungoma County Hospital, (3) Webuye Sub-County Hospital, (4) Nakuru County Teaching and Referral Hospital, (5) Thika Level 5 Hospital and (6) Naivasha Sub-County Hospital.
The study design will encompass a preimplementation phase, a stepwise implementation phase and an endline study to measure the changes in outcomes between the phases. A baseline study on antibiotic usage (defined daily doses (DDD) per 1000), antibiotic resistance (culture and genetic markers), antibiotic de-escalation, duration of hospital stays, rates of readmission, prescription patterns and cost analysis will be carried out in the preimplementation phase. The intervention, which is the use of antibiotic guidelines and ASPs, will be instituted in the 6 county hospitals for 18 months. The stepwise implementation phase will involve introduction of interventions as well as monitoring and evaluation of their effectiveness, and thereafter improving the interventions where necessary. The strategy will facilitate learning cycles every 4–6 weeks and continuous improvement of stewardship activities and updating of guidelines to reflect evolving antibiotic needs in diverse settings. During the intervention phase, challenges faced during the implementation of the guidelines will be documented and used to advise on the changes required during the review of the guidelines. The endline study will be conducted and differences between the two phases evaluated as per statistical analysis.

In the baseline and endline studies, multidisciplinary strategies will be employed as follows
1. Knowledge of healthcare workers, attitudes and practices on antibiotic resistance, guidelines and ASP will be studied qualitatively and quantitatively.
2. Basic science approaches, encompassing antibiotics culture sensitivity and molecular biology-genetic markers of resistance, will be analysed.
3. Clinical patient outcomes will be studied to evaluate the guidelines.
4. Health economics cost savings on using guidelines and ASP will be evaluated.

Antibiotic guidelines and ASPs: development
Antibiotic guidelines will be formulated in consultation with senior clinicians in the study hospitals taking into account each hospital’s antimicrobial resistance patterns. The ASP committee will comprise a hospital physician, a microbiologist and a pharmacist. Broad-spectrum antibiotic prescriptions will be brought to the attention of the ASP committee members. The committee members will perform regular ward rounds, three times a week, in the initial stages. This will be reduced to once a week later in the project, to optimise adherence to antibiotic guidelines. Furthermore, the guidelines will be promoted through training sessions, provision of pocket-size guideline cards to clinicians and pharmacists, large poster displays in the wards and through hospital and project websites and social media.

Data collection
Laboratory assessment tools will be used to determine the preparedness of the laboratories to perform antibiotic sensitivity tests (see online supplementary file 1). The tool will assess whether the laboratories have the equipment necessary to perform bacterial culture, identification and susceptibility testing, such as carbon dioxide incubators, safety cabinets and refrigerators. The tool will also determine whether the laboratories have the internationally recommended guidelines to perform susceptibility and quality assurance tests. In addition, knowledge, attitude and practices (KAPs) about antibiotic prescription and resistance among medical practitioners will be assessed using a KAP tool (see online supplementary file 2). The tool will target those medical practitioners, who usually prescribe antimicrobial drugs in the hospitals and will include the consultants, medical officers as well as interns, clinical officers and pharmacists. The KAP tool will also determine the guidelines that the prescribers use to decide on the appropriate antimicrobial drug. A health system assessment tool will be employed to gather baseline information on the antimicrobial stewardship activities in each hospital (see online supplementary file 3). Information on bed occupancy, antibiotic usage and antibiotic resistance data will be collected from each of the hospital information systems, pharmacy management systems and laboratory reporting systems, respectively. Antibiotic usage will be analysed in order to determine the impact of the intervention on antibiotic usage comparing the intervention and the control arms. Data on antibiotics issued to adult and children inpatients only will be factored, excluding discharge and outpatient supplies.

To consistently compare antibiotic usage, the DDD will be used and expressed per 1000 occupied bed days (OBDs) to account for fluctuations in activity following WHO guidelines. The OBDs will be obtained from the hospital information systems.

Culture sensitivity and genetic analyses
Nasal swabs or tracheal aspirate, urine, wound swabs and blood samples will be taken from patients who have consented to the study for bacteriological analysis. Samples will be subjected to standard bacteriological analysis to isolate the culprit bacteria. Bacterial species will be confirmed by use of biochemical test and analytical profiles index API strips (bioMérieux France). Antimicrobial susceptibility tests will be performed on isolated bacteria as per the Kirby-Bauer method following manufacturer’s instruction. Results will be interpreted using the Clinical and Laboratory Standards Institute tables.

Any bacteria isolate found to be resistant to third generation cephalosporins will be tested for production of extended spectrum beta-lactamase (ESBL) using the synergy disk diffusion test. Vancomycin-resistant *Enterococcus* (VRE) will be identified using disc diffusion tests. Methicillin-resistant *Staphylococcus aureus* (MRSA) will be detected by testing isolates resistant to cefoxitin using the E test (AB Biodisk, Solna, Sweden) on Mueller-Hinton

---

**Design**

The study will use the Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) conceptual framework. RE-AIM involves the interaction of all the five factors and fits well with approaches that are system based. The study design will encompass a preimplementation phase, a stepwise implementation phase and an endline study to measure the changes in outcomes between the phases. A baseline study on antibiotic usage (defined daily doses (DDD) per 1000), antibiotic resistance (culture and genetic markers), antibiotic de-escalation, duration of hospital stays, rates of readmission, prescription patterns and cost analysis will be carried out in the preimplementation phase. The intervention, which is the use of antibiotic guidelines and ASPs, will be instituted in the 6 county hospitals for 18 months. The stepwise implementation phase will involve introduction of interventions as well as monitoring and evaluation of their effectiveness, and thereafter improving the interventions where necessary. The strategy will facilitate learning cycles every 4–6 weeks and continuous improvement of stewardship activities and updating of guidelines to reflect evolving antibiotic needs in diverse settings. During the intervention phase, challenges faced during the implementation of the guidelines will be documented and used to advise on the changes required during the review of the guidelines. The endline study will be conducted and differences between the two phases evaluated as per statistical analysis.

In the baseline and endline studies, multidisciplinary strategies will be employed as follows

1. Knowledge of healthcare workers, attitudes and practices on antibiotic resistance, guidelines and ASP will be studied qualitatively and quantitatively.
2. Basic science approaches, encompassing antibiotics culture sensitivity and molecular biology-genetic markers of resistance, will be analysed.
3. Clinical patient outcomes will be studied to evaluate the guidelines.
4. Health economics cost savings on using guidelines and ASP will be evaluated.

**Antibiotic guidelines and ASPs: development**

Antibiotic guidelines will be formulated in consultation with senior clinicians in the study hospitals taking into account each hospital’s antimicrobial resistance patterns. The ASP committee will comprise a hospital physician, a microbiologist and a pharmacist. Broad-spectrum antibiotic prescriptions will be brought to the attention of the ASP committee members. The committee members will perform regular ward rounds, three times a week, in the initial stages. This will be reduced to once a week later in the project, to optimise adherence to antibiotic guidelines. Furthermore, the guidelines will be promoted through training sessions, provision of pocket-size guideline cards to clinicians and pharmacists, large poster displays in the wards and through hospital and project websites and social media.

**Data collection**

Laboratory assessment tools will be used to determine the preparedness of the laboratories to perform antibiotic sensitivity tests (see online supplementary file 1). The tool will assess whether the laboratories have the equipment necessary to perform bacterial culture, identification and susceptibility testing, such as carbon dioxide incubators, safety cabinets and refrigerators. The tool will also determine whether the laboratories have the internationally recommended guidelines to perform susceptibility and quality assurance tests. In addition, knowledge, attitude and practices (KAPs) about antibiotic prescription and resistance among medical practitioners will be assessed using a KAP tool (see online supplementary file 2). The tool will target those medical practitioners, who usually prescribe antimicrobial drugs in the hospitals and will include the consultants, medical officers as well as interns, clinical officers and pharmacists. The KAP tool will also determine the guidelines that the prescribers use to decide on the appropriate antimicrobial drug. A health system assessment tool will be employed to gather baseline information on the antimicrobial stewardship activities in each hospital (see online supplementary file 3). Information on bed occupancy, antibiotic usage and antibiotic resistance data will be collected from each of the hospital information systems, pharmacy management systems and laboratory reporting systems, respectively. Antibiotic usage will be analysed in order to determine the impact of the intervention on antibiotic usage comparing the intervention and the control arms. Data on antibiotics issued to adult and children inpatients only will be factored, excluding discharge and outpatient supplies.

To consistently compare antibiotic usage, the DDD will be used and expressed per 1000 occupied bed days (OBDs) to account for fluctuations in activity following WHO guidelines. The OBDs will be obtained from the hospital information systems.

**Culture sensitivity and genetic analyses**

Nasal swabs or tracheal aspirate, urine, wound swabs and blood samples will be taken from patients who have consented to the study for bacteriological analysis. Samples will be subjected to standard bacteriological analysis to isolate the culprit bacteria. Bacterial species will be confirmed by use of biochemical test and analytical profiles index API strips (bioMérieux France). Antimicrobial susceptibility tests will be performed on isolated bacteria as per the Kirby-Bauer method following manufacturer’s instruction. Results will be interpreted using the Clinical and Laboratory Standards Institute tables.

Any bacteria isolate found to be resistant to third generation cephalosporins will be tested for production of extended spectrum beta-lactamase (ESBL) using the synergy disk diffusion test. Vancomycin-resistant *Enterococcus* (VRE) will be identified using disc diffusion tests. Methicillin-resistant *Staphylococcus aureus* (MRSA) will be detected by testing isolates resistant to cefoxitin using the E test (AB Biodisk, Solna, Sweden) on Mueller-Hinton.
agar supplemented with 2% NaCl and incubated at 37°C for 24 hours. The identified ESBL, VRE and MRSA samples will be analysed by PCR and sequencing to identify the resistance genotype. In vitro conjugation tests will be performed to determine if resistance in bacteria is transferable.

**CBA for the use of antibiotic guidelines and ASP**

A CBA from a health facility and a national perspective will be performed. For health facilities, three cost drivers will be considered: (1) pharmacy spending, (2) length of stay and (3) antimicrobial stewardship interventions (training, infection control measures and so on). At country level, we will consider disability-adjusted life years, work-days lost and cost of treatment.\(^{25-27}\) This will be done by collecting and analysing data on patient income, length of hospital stay, death or disability occasioned by drug-resistant pathogens, hospital pharmacy expenditure and cost of training/rolling out antimicrobial stewardship guidelines. This data will be collected before and after antimicrobial stewardship interventions.

**Study size**

**Prevalence of inappropriate use of broad-spectrum antibiotics**

The sample size is based on the prevalence of inappropriate use of broad-spectrum antibiotics, documented as being about 50% in South Africa.\(^{11}\) To detect a reduction of the 50% inappropriate use of broad-spectrum antibiotics by 20%–30% with a power of 90% and \(\alpha\) of 0.05 in a two-sided test, a sample size of 410 in each county hospital would be adequate. In order to detect a reduction (20%) but with a power 80%, the sample size would be 320 as shown in figure 1. With a 15% allowance for loss to follow-up, a total of about 500 participants would be sufficient in each of the selected county hospitals. Therefore, we shall evaluate the prevalence of inappropriate use of broad-spectrum antibiotics in 500×6= 3000 patients from the six facilities.

**Prevalence of antibiotic resistance**

The sample size is based on the prevalence of antibiotic resistance of 78%\(^{15}\) in 2004 at Kenyatta National Hospital, Kenya. To detect a reduction of the 78% antibiotic resistance by 10%–68% with a power of 90% and \(\alpha\) of 0.05 two-sided test, a sample size of 500 in each county hospital would be adequate; while to achieve a reduction of 10% with power 80%, the sample size would need to be 220 (figure 2). With 15% allowance for loss to follow-up, a total of 600 participants would be sufficient in each of the selected county hospitals. Therefore, we shall evaluate the prevalence of resistance in 600×6 = 3600 patients for the 6 facilities.

**Data management**

Data will be recorded on a standardised case report form at every hospital by the trained study staff. The data will be held locally and uploaded to the secure central study server hosted at the Mount Kenya University main campus in Thika. This will be overseen by the data manager/statistician, who will run regular reconciliation to derive the final study database. Access to the study database will be restricted and password protected. The data will be stored in excel, jpeg and word files for the electronic cases. For archiving purposes, the Mount Kenya University electronic repository will be used to ensure that the data are publicly available. Collected data will be retained according to the policy governing the Mount Kenya University repository. The principal investigators involved in this study do not have any reasons that might prohibit the sharing of the data emanating from the study.

**Statistical analysis**

The data will be analysed using qualitative and quantitative methods. Qualitative data will be analysed by subjecting the information to content analysis and presenting it in different emerging themes. The summaries of the data emanating from these themes will then be arranged on a case-by-case basis through the use of an Excel spreadsheet\(^{28}\) and the analyses performed using

---

**Figure 1** Statistical power analysis for sample size determination for the prevalence of inappropriate use of broad-spectrum antibiotics.

**Figure 2** Statistical power analysis for sample size determination for the prevalence of antibiotics resistance.

---
NVivo software. Quantitative data analyses will be carried out using Stata V.14 (Stata). The differences between baseline and endline on all the study outcomes will be compared using appropriate statistical methods, such as McNemar's test, paired t-test and the Wilcoxon signed-rank test (non-parametric test), accounting for pairing and clusters (hospitals). Multivariable log-binomial regression analysis will be used to elucidate risk factors for antibiotic resistance.

ETHICS AND DISSEMINATION

Approvals to carry out the study have been obtained from the National Coordinating Committee for Science, Technology and Innovation (NACOSTI) (NACOSTI/P/18/33304/25986) and the Mount Kenya University Ethics Review Committee (MKU/ERC/0764). In addition, permission was obtained from each of the participating hospitals. This entailed submission of an introduction letter attaching the certificate of clearance from NACOSTI and the ethical review certificate from MKU. In Thika, Nakuru and Naivasha, a research fee was paid as required by the hospital board. The study will follow all provisions of the Declaration of Helsinki. Participants in the study will not incur any cost associated with the transport or processing of the samples; neither will they receive any monetary inducements to participate in the study. Material transfer to laboratories outside of Kenya shall not be undertaken in this study. Informed written consent will be sought from the participants enrolled in the study.

Obtained results will be disseminated via different streams, including research conferences and in peer-reviewed journals. We are aiming for five publications to be generated by the end of the study. These will include the study protocol itself and the different aspects emerging during in the course of the project. Contextualised guidelines on judicious use of antibiotics in the six hospitals in Kenya will also be published in the Ministry of Health’s website and that of the collaborating hospitals for easy access by other health facility in and outside Kenya. In addition, the findings will be shared in a dissemination forum bring together members of the health management teams at both the country and county levels, clinicians who do prescription of antimicrobial drugs, researchers, members of the public and other key stakeholders. The dissemination forum will be held once at the end of the study.

Exit strategy and stakeholder involvement

The study is mainly targeting clinicians who do antimicrobial prescription and, therefore, patients will not be directly involved in the study. Reports obtained from this study will, however, be made available to the patients in the participating hospital through a dissemination forum and to the general public through publications.

Patient and public involvement

In the process of developing this protocol, we have engaged physicians working in the proposed county hospitals, and they have identified the challenge of antibiotic resistance as real and appreciate the opportunities that use of antibiotic guidelines and ASPs may provide in combating resistance, improving clinical care and saving costs. We plan to continue involving all the stakeholders in the process, including clinicians, laboratory personnel, pharmacists, public health officials, patients and scientists. We anticipate that the study findings will inform county and national policy on mitigating antibiotic resistance and raise public awareness on the need for judicious use of antibiotics. The project will use social media platforms, websites of the collaborating institutions and publications in peer-reviewed journals, local dailies and presentations in scientific meetings to further engage stakeholders and the public on this important issue and enhance the learning approach inherent in the strategy of implementation science for improved performance of the ASPs and the study in general. In case any of the hospitals dropout either during the baseline phase or early stages of the implementation phase, another hospital will be brought onboard. Replacements will not be considered during the late stages of the project.

DISCUSSION

The emergence of antimicrobial-resistant pathogens and a lack of new drugs to effectively treat these pathogens are the two main challenges in human health. There is thus the need to advocate the proper use of the currently available antimicrobial agents by safeguarding their effectiveness. Antibiotic stewardship has been shown to contribute to reducing antibiotic resistance, but this strategy has not been rolled out in most sub-Saharan countries in level 4 and 5 hospitals. The proposed work will employ an implementation research approach to evaluate the best strategies and derive lessons on mainstreaming antibiotic stewardship in these facilities. By leveraging on a health system approach, the implementation research will unravel real-life impediments and opportunities by working with hospital teams to codesign execution plans, monitor and evaluate and the sustainability of the stewardship programmes.

Most hospitals in Kenya lack the capacity to carry out antimicrobial sensitivity tests, due to the lack of resources and technical knowhow, among other challenges. This study will first provide an assessment to determine the challenges hospitals are facing; this will be done through interviews with clinicians and assessment of the capacity of the laboratories to perform the sensitivity tests. These steps will make up the initial phase and will guide the nature of implementations to be used during the implementation phase. It is hoped that the project will capacitate the laboratories in the six hospitals to do the tests and sensitise the clinicians on the need to prescribe antimicrobial drugs based on results obtained from the laboratory tests. After the implementation phase, the endline phase will involve surveys similar to those conducted during the baseline phase. This will allow determination
Table 1  Proposed study timelines

<table>
<thead>
<tr>
<th>Activity</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethics clearance and authorisation from study sites</td>
<td>Q1</td>
<td>Q2</td>
<td>Q3</td>
</tr>
<tr>
<td>Baseline study on prevalence of antibiotic resistance and stewardship activities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Identification of members for the antibiotic stewardship programmes (ASPs)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Development of antibiotic guidelines</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adopting and preparing materials for ASP training</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Development of antibiotic guidelines and stewardship mobile application</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Training the ASP members</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collecting data on antibiotic usage in the hospitals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Conducting KAPs study on use of guidelines and ASPs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Analyse and present antibiotic resistance data using maps and charts</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Presenting findings to stakeholders and preparing the final report</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

KAP, knowledge, attitude and practices.

of the impact of the implementation strategies taken in reducing the cost of treatment, length of hospital stay and burden on the health system, among others.

The hospital management teams play a key role in determining the allocation of resources to and within the hospitals. In this project, we have proposed to involve hospital management by including its members in the stewardship committees that will be established. This will ensure that the management is well informed about the challenges in the sections involved in surveillance and the progress that is being made. Involvement of the hospital management will also ensure that there is a buy-in of the recommendations made by the stewardship committee.

Although there is the need to establish antimicrobial stewardship committees in all the hospitals, the project proposes to start with the selected six hospitals with the hope that the same can be reproduced by other hospitals to establish similar committees in their hospitals.

Study timeline

The study is designed for a 3-year period. Enrolment already started in 2018 and participant recruitment will continue up to 2020 (table 1). So far, stewardship committees have been established and workshops to sensitise the members conducted. Data collection on KAP of antibiotic prescribers in the hospitals is already in progress.

Author affiliations
1Research and Innovation, Mount Kenya University, Thika, Kenya
2Department of Animal Health and Production, Maasai Mara University, Narok, Kenya
3Department of Medical Laboratory Sciences, Kenya Medical Training College, Nairobi, Kenya
4Department of Medical Microbiology, University of Nairobi College of Health Sciences, Nairobi, Kenya
5Department of Pathology, Aga Khan University, Nairobi, Kenya
6Clinical Trial Facility, KEMRI/Wellcome Trust, Kilifi, Kenya
7Centre for Infectious and Parasitic Diseases Control Research, Kenya Medical Research Institute, Nairobi, Kenya

Contributors  JG initiated the concepts of the study. JG, DM, DN, MMasika, GO, MN, FMakokha, PM, RM, FMuregi and MMwau developed the protocol. JG, DM, DN and MMasika will be involved in training the ASCs. DM, GO, MN, FMakokha, PM, RM, DN and MK will help in data collection. MN and MK will be involved in data analysis. MK wrote the first draft of the manuscript. All authors reviewed and approved the protocol.

Funding  This work was supported by The Kenya National Research Fund (grant number NRF/MKU/2017/007 to JG).

Competing interests  None declared.

Patient and public involvement  Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication  Not required.

Provenance and peer review  Not commissioned; externally peer reviewed.

Open access  This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD  Moses Kamita http://orcid.org/0000-0002-1756-932X
REFERENCES

5. WHO. United nations meeting on antimicrobial resistance, 2016.
24. CML. Performance standards for antimicrobial susceptibility testing, 2019.